Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 6, 2008, Pages 1137-1143

  Gleissner, Christian A ^a   Sanders, John M ^b   Nadler, Jerry ^c   Ley, Klaus ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Atherosclerosis; Diabetes mellitus; Lipoproteins; Macrophage; Plaque

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE REDUCTASE; CHLORDANE; EPALRESTAT; LOW DENSITY LIPOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; 4-HYDROXY-2-NONENAL; ALDEHYDE; DRUG DERIVATIVE; ENZYME INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; RHODANINE; THIAZOLIDINE DERIVATIVE;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; FLUORESCENCE; FOAM CELL; GENE ACTIVITY; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; OSMOSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; RISK FACTOR;

ADULT; ALDEHYDE REDUCTASE; ALDEHYDES; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; FOAM CELLS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; RHODANINE; RISK FACTORS; THIAZOLIDINES; UP-REGULATION;

EID: 44849131679     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.158295     Document Type: Article

References (38)

1. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med. 2000;342:1040-1042.
2. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vase Biol. 2004;24:1542-1548.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
4. GIeissner CA, Galkina E, Nadler JL, Ley K. Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today. In press.
5. Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep. 2007;7:242-248.
6. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A. Aldose reductase induction: A novel response to oxidative stress of smoodi muscle cells. FASEB J. 1997;11:181-188.
7. Rittner HL, Hafner V, Klimiuk PA, Szweda LI, Goronzy JJ, Weyand CM. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest. 1999; 1.03:1007-1.0.1.3.
8. Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci. 1994;15:293 297.
9. Lo AC, Cheung AK, Hung VK, Yeung CM, He QY, Chiu JF, Chung SS, Chung SK. Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab. 2007;27: 1496-1509.
10. Petrash JM. All in the family: Aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci. 2004;61:737-749.
11. Kyselova Z, Stefek M, Bauer V. Pharmacological prevention of diabetic cataract. J Diabetes Complications. 2004;18:129-140.
12. Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia. 1992;35:499-504.
13. McHugh JM, McHugh WB. Diabetes and peripheral sensory neurons: What we don't know and how it can hurt us. AACN Clin Issues. 2004; 15:136-149.
14. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care. 2006;29:1538-1544.
15. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallara K, Tall AR, Ramasamy R, Goldberg IJ. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest. 2005; 115:2434-2443.
16. Cho HJ, Shashkin P, Gleissner CA, Dunson D, Jain N, Lee JK, Miller Y, Ley K. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics. 2007;29:149-160.
17. Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, Schmitz G. Enzymatically degraded LDL preferentially binds to cd'14(high) cdl6( + ) monocytes and induces foam cell formation mediated, only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vase Biol. 2001; 21:1004-1010.
18. Reutershan J, Morris MA, Burcin TL, Smith DF, Chang D, Saprito MS, Ley K. Critical role of endothelial C.XCR2 in LPS-induced neutrophil migration into die lung. J Clin Invest. 2006;116:695-702.
19. Pfaffl MW. A new matiiemaucal model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
20. Wermuth B, von Wartburg JP. Aldose reductase from human tissues. Methods Enzymol. 1982;89:181-186.
21. Mizuno K, Suzuki T, Tanaka T, Taniko K. Inhibitory effects of fidarestat on aldose reductase and aldehyde reductase activity evaluated by a new method using hplc with post-column spectrophotometric detection. Biol Pharm Bull. 2000;23:244-248.
22. Ishii A, Kotani T, Nagaki Y, Shibayama Y, Toyomaki Y, Okukado N, Ienaga K, Okamoto K. Highly selective aldose reductase inhibitors. 1. 3-(arylalkyl)-2,4,5-trioxoimidazolidine-l-acetic acids. J Med Chem. 1996;39:1924 1927.
23. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest.1996;98: 2572-2579.
24. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: Beyond lipid uptake. Arterioscler Thromb Vase Biol. 2006;26:1702-1711.
25. Ramana KV, Srivastava SK. Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages. Cytokine. 2006;36:115-122.
26. Fischer B, von Knethen A, Brune B. Dualism of oxidized lipoproteins in provoking and attenuating the oxidative burst in macrophages: Role of peroxisome proliferator-activated receptor-y. J Immunol. 2002;1.68: 2828-2834.
27. Ruef J, Liu SQ, Bode C, Tocchi M, Srivastava S, Runge MS, Bhatnagar A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb Vase Biol. 2000;20:1745 1752.
28. Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta. 1996;1304:65-84.
29. Markus HB, Raducha M, Harris H. Tissue distribution of mammalian aldose reductase and related enzymes. Biochem Med. 1983;29:31-45.
30. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes. 2006;55:2757-2762.
31. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hypergiycaemic damage. Nature. 2000;404:787 790.
32. Kuzumoto Y, Kusunoki S, Kato N, Kihara M, Low PA. Effect, of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. Diabetologia. 2006;49:3085-3093.
33. Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-a-induced expression of adhesion molecules in endodielial cells. FASEB J. 2004;18:1209-1218.
34. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam ceils. Curr Pharm Des. 2005;11:3061-3072.
35. Griendling KK. Novel NAD(P)H oxidases in die cardiovascular system. Heart. 2004;90:491-493.
36. Danesh FR, Wada J, Wallner EI, Saliai A, Srivastava SK, Kanwar YS. Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pauiobiology of diabetes mellitus. Curr Med Chem, 2003; 1.0:1399-1406.
37. Dent MT, Tebbs SE, Gonzalez AM, Ward JD, Wilson RM. Neutrophil aldose reductase activity and its association with established diabetic microvascular complications. Diabet Med. 1991;8:439-442.
38. Takahashi Y, Tachikawa T, Ito T, Takayama S, Omori Y, Iwamoto Y. Erythrocyte aldose reductase protein: A. clue to elucidate risk factors for diabetic neuropathies independent of glycemic control. Diabetes Res Clin Pract. 1998;42:101-107.